Clinical trials: Severe Alcohol Use Disorder
Alcohol Use Disorder, Severe
Inpatient Single Dose Interventions for Alcohol Use Disorder
Every year, alcohol use disorder (AUD) generates millions of emergency department (ED) visits and hospital admissions, costing the U.S. health sector over $90 billion.
- Trial name
- NCT04562779
- Testing
- Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Denver Health and Hospital Authority
Substance Use, Severe Mental Disorder
Validation of the Dutch Translation of the Tobacco, Alcohol, Prescription Medication and Other Substances (TAPS)-Tool
The aim of the study is to investigate the reliability and validity of the Dutch version of the TAPS-tool. This will be investigated in 2 groups: patients without intellectual disabilities treated in Flexible Assertive Community…
- Conditions
- Substance Use, Severe Mental Disorder, Intellectual Disability, Mild
- Trial name
- NCT05273021
- Testing
- TAPS
- Where
- 3 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Birgit Seelen-de Lang
Alcohol Abuse
Perception of the Risks of Alcohol and Individual Vulnerabilities in Young Adults
Alcohol use is the second leading cause of preventable death after smoking. The Evin law was built in 1991 with the goal of reducing exposure to alcohol marketing among the youngest.
- Trial name
- DEPREV (NCT03876132)
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Brest
Depression - Major Depressive Disorder, Schizophenia Disorder
A Novel Blood Test as a Biomarker in Mental Health
This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital…
- Conditions
- Depression - Major Depressive Disorder, Schizophenia Disorder, Psychosis, Mania (Neurotic)
- Trial name
- LEADING-MH (NCT06856161)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Fraser Health
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)
To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.
- Conditions
- Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD), Comorbidities and Coexisting Conditions
- Trial name
- KET-DUAL (NCT07247370)
- Testing
- Ketamine, Cognitive Behavioural Therapy
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- South West Sydney Local Health District
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
- Trial name
- NCT07405606
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health